Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?
暂无分享，去创建一个
P. Gibbs | B. Tran | M. IJzerman | L. Spain | A. Azad | P. Parente | R. Mahar | F. Parnis | E. Kwan | A. Weickhardt | A. Gunjur | J. Torres | Shirley S. Wong | A. Anton | J. Shapiro | J. Goh | F. Franchini | A. Pereira-Salgado | C. Steer | Stephen Brown